Literature DB >> 21248159

Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.

H Findlow1, R Borrow, P Hardelid, E Newton, S Frankland, S Naylor, E Miller, E Kaczmarski, R C Read.   

Abstract

Limited data are available on the kinetics of meningococcal serogroup C (MenC)-specific antibody responses following parenteral or nasal challenge in those who have received prior MenC vaccination (polysaccharide or conjugate). Young adults who had previously received either meningococcal A/C polysaccharide (MACP) or MenC conjugate (MCC) vaccine or naïve subjects were challenged with MACP via one of two routes, nasal or parenteral. Blood samples were taken prevaccination and on days 1 to 4 and day 10 postvaccination. MenC serum bactericidal antibody (SBA) and MenC-specific IgG were measured. Following parenteral challenge, MenC SBA and IgG responses were seen to occur between 4 and 7 days postchallenge. A lower proportion of subjects responded following nasal challenge, with naïve subjects showing little change in SBA geometric mean titer (GMT) and IgG geometric mean concentration (GMC) over the 10 days following challenge. Increases in SBA GMTs were seen between 4 and 7 days after nasal challenge in those who had received prior MCC and between 7 and 10 days in those who had received prior MACP, and the responses in the prior-MACP group were of lower magnitude than the responses of the prior-MCC group. The data presented here indicate that, following MCC vaccination, memory has been induced at the mucosal level, and these subjects were able to respond with increases in SBA levels. These results demonstrate that the speed of response (primary or secondary) to challenge with MenC polysaccharide via the nasal or parenteral route does not differ and support concerns that immunological memory alone is too slow to provide protection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248159      PMCID: PMC3067375          DOI: 10.1128/CVI.00503-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  25 in total

1.  Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants.

Authors:  Qibo Zhang; Emily Pettitt; Roger Burkinshaw; Gillian Race; Lynne Shaw; Adam Finn
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

2.  Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.

Authors:  Martin C J Maiden; James M Stuart
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

3.  Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children.

Authors:  A Nurkka; J MacLennan; V Jäntti; S Obaro; B Greenwood; H Käyhty
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

4.  Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.

Authors:  Richarda M de Voer; Fiona R M van der Klis; Carla W A M Engels; Rutger M Schepp; Jan van de Kassteele; Elisabeth A M Sanders; Ger T Rijkers; Guy A M Berbers
Journal:  Vaccine       Date:  2009-10-01       Impact factor: 3.641

5.  Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.

Authors:  Ray Borrow; David Goldblatt; Nick Andrews; Jo Southern; Lindsey Ashton; Sarah Deane; Rhonwen Morris; Keith Cartwright; Elizabeth Miller
Journal:  J Infect Dis       Date:  2002-10-08       Impact factor: 5.226

6.  Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naïve controls.

Authors:  R Borrow; J Southern; N Andrews; N Peake; R Rahim; M Acuna; S Martin; E Miller; E Kaczmarski
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

7.  Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.

Authors:  Q Zhang; R Lakshman; R Burkinshaw; S Choo; J Everard; S Akhtar; A Finn
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

8.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

9.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

Authors:  E Miller; D Salisbury; M Ramsay
Journal:  Vaccine       Date:  2001-10-15       Impact factor: 3.641

10.  Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents.

Authors:  Q Zhang; S Choo; J Everard; R Jennings; A Finn
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

View more
  2 in total

1.  Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine.

Authors:  Johannes Elias; Jamie Findlow; Ray Borrow; Angelika Tremmel; Matthias Frosch; Ulrich Vogel
Journal:  J Occup Med Toxicol       Date:  2013-03-04       Impact factor: 2.646

2.  Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?

Authors:  Susanne P Stoof; Anne-Marie Buisman; Debbie M van Rooijen; Rianne Boonacker; Fiona R M van der Klis; Elisabeth A M Sanders; Guy A M Berbers
Journal:  PLoS One       Date:  2015-10-12       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.